March 1, 2018 (Vol. 38, No. 5)
Lonza
Pichia pastoris was designed as a valuable alternative to Escherichia coli and CHO cells for production of novel protein formats such as multi-specific antibody mimetics. The new XS™ Pichia 2.0 system designed to provide high product titers (up to 6 g/L) for these novel compounds along with a fast, robust and scalable manufacturing process suitable for commercial production or development. The XS™ Pichia 2.0 is complemented by an effective high-throughput screening, which assures identification of high-performing clones under fed-batch conditions.
